Revised forecast
Fiscal year ending March 2027 · Second quarter (interim period)Previous forecast published 7 August 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Because performance remained strong, particularly in the Americas, net sales, operating profit, profit before tax, and interim profit attributable to owners of the parent are expected to exceed the previous forecasts. The impairment loss will be recognized because the review of the launch timing for the overseas business was reflected in the business plan and future cash flow estimates were revised, resulting in a determination that the recoverable amount was lower than the carrying amount.
Impairment loss of ¥5,769 million relating to goodwill recognized upon the acquisition of Sysmex BioMajesty Co., Ltd., and tangible fixed assets and intangible assets held by the company
| Item | Details |
|---|---|
| Net Sales | ¥265,000 million → ¥272,000 million（+3.0%） |
| Operating profit | ¥25,000 million → ¥33,000 million（+32.0%） |
| Profit attributable to owners of the parent | ¥15,000 million → ¥17,000 million（+13.0%） |
| Net income per share | 24.68 yen and sen → 29.47 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Second quarter (interim period) |
| Publication date of previous forecast | 7 August 2026 |
| Previous-period results | Net Sales 232,527 Millions of yen (yen and sen for per-share amounts) / Operating profit 32,957 Millions of yen (yen and sen for per-share amounts) / Pretax profit 29,955 Millions of yen (yen and sen for per-share amounts) / Interim profit attributable to owners of the parent 19,019 Millions of yen (yen and sen for per-share amounts) / Basic interim earnings per share 30.5 Millions of yen (yen and sen for per-share amounts) |
| Reason for the revision | Because performance remained strong, particularly in the Americas, net sales, operating profit, profit before tax, and interim profit attributable to owners of the parent are expected to exceed the previous forecasts. The impairment loss will be recognized because the review of the launch timing for the overseas business was reflected in the business plan and future cash flow estimates were revised, resulting in a determination that the recoverable amount was lower than the carrying amount. |
| Details and amount of extraordinary loss | Impairment loss of ¥5,769 million relating to goodwill recognized upon the acquisition of Sysmex BioMajesty Co., Ltd., and tangible fixed assets and intangible assets held by the company |
| Dividend forecast revision | No revision (unchanged from the details announced on 14 May 2026) |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Performance remained strong, particularly in the Americas, prompting an upward revision to the interim earnings forecasts. Meanwhile, the review of the launch timing for Sysmex BioMajesty's overseas business was reflected in the business plan, and future cash flow estimates were revised. As a result, the recoverable amount was determined to be lower than the carrying amount, and an impairment loss will be recognized.